Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019. Issue 10 (3rd October 2021)

• Record Type: Journal Article
• Authors: de Oliveira Costa, Juliana; Gianacas, Christopher; Beard, Frank; Gonzalez-Chica, David; Chidwick, Kendal; Osman, Rawa; MacIntyre, C. Raina; Havard, Alys
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 10(2021)
• Page Start: 3692
• Page End: 3701
• Publication Date: 2021-10-03
• Subjects: meningococcal -- vaccination coverage -- adolescent -- smokers -- immunocompromised host -- general practice; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.1923349
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Neisseria meningitidis serogroup B (MenB) is the most common cause of meningococcal disease in adolescents and young adults. In Australia, MenB vaccination has been available through private prescription since 2014 and has been recommended for at-risk groups including adolescents, young adults who smoke and people medically at risk. For each of these at-risk groups, we estimated cumulative annual coverage of MenB vaccination between 2014 and 2019. We also evaluated factors associated with vaccination coverage in 2019. Our analyses used electronic health records in the national MedicineInsight database for people regularly attending general practices. Cumulative vaccination coverage increased among the at-risk groups between 2014 and 2019: from 0.09% to 1.65% for adolescents, from 0.01% to 0.15% for young adults who smoke, and from 0.35% to 12.09% for people medically at risk. However, vaccination coverage in 2019 remained very low across these groups. Data sparsity prevented the evaluation of factors associated with vaccination coverage for smokers. We observed variation in the relative risk of being vaccinated by age, sex, socioeconomic and clinical factors for adolescents and people medically at risk. Still, the absolute magnitude of coverage was low across all subgroups examined, and indicates a need for strategies to increase vaccination uptake among at-risk groups irrespective of patient and practice characteristics. Our study provides baseline data for monitoring menB vaccination uptake among recommended groups in light of limited national data, especially for medically at-risk groups.